Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CEOP-IMVP-Dexa regimen

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Primary end point of this trial was to reduce neutropenic infections during the treatment of aggressive NHL with CEOP/IMVP-Dexa… Expand
Is this relevant?
2012
2012
Abstract Background/Purpose Elderly lymphomas are usually defined as disease onset at age more than 60 years according to the… Expand
Is this relevant?
2009
2009
This study aimed to determine whether dose-dense therapy improves 3-year survival over the standard therapy for untreated… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 5
Is this relevant?
2004
2004
A 6-year-old male child was consulted in our ambulatory in Goundi missionary hospital in South Chad, in September 2001. He… Expand
Is this relevant?
2004
2004
A 6-year-old male child was consulted in our ambulatory in Goundi missionary hospital in South Chad, in September 2001. He… Expand
Is this relevant?
1997
1997
Primary end point of this trial was to reduce neutropenic infections during the treatment of aggressive NHL with CEOP/IMVP-Dexa… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
1996
1996
PURPOSE This trial evaluated the efficacy, toxicity, and practicability of a new intensive chemotherapy regimen in a multicenter… Expand
Is this relevant?
1995
1995
We report on a 28 year old Turkish woman, who was admitted to our hospital with the symptoms of malabsorption and protein-loosing… Expand
Is this relevant?
1991
1991
A combination of two non-cross-resistant regimens, CEOP and IMVP-Dexa given every 4 weeks, three to six times according to… Expand
Is this relevant?